Nebraska Cancer Specialists

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

Ranjana H. Advani, Joseph J. Buggy, Jeff P. Sharman et al. · Journal of Clinical Oncology · 2012 · 1.1K citations · Full text

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Arlene Chan, Suzette Delaloge, Frankie A. Holmes et al. · The Lancet Oncology · 2016 · 551 citations

Breast Oncology, Health Sciences, Medicine +9

IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection

Jason Beiko, Dima Suki, Kenneth R. Hess et al. · Neuro-Oncology · 2013 · 462 citations · Full text

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced <i>BRAF</i>-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

Michael B. Atkins, Sandra J. Lee, Bartosz Chmielowski et al. · Journal of Clinical Oncology · 2022 · 402 citations · Full text

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma

Neil D. Gross, David M. Miller, Nikhil I. Khushalani et al. · New England Journal of Medicine · 2022 · 288 citations · Full text